{"id":35195,"date":"2015-04-27T09:33:21","date_gmt":"2015-04-27T13:33:21","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=35195"},"modified":"2015-04-27T09:33:21","modified_gmt":"2015-04-27T13:33:21","slug":"the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195","title":{"rendered":"The U.S. FDA Granted Priority Review To AbbVie Inc (NYSE:ABBV) Hepatitis C Drug"},"content":{"rendered":"<p style=\"text-align: justify;\">The U.S. FDA <a href=\"http:\/\/www.wsj.com\/articles\/abbvie-hepatitis-c-drug-granted-priority-fda-review-1429883327\">granted<\/a> priority review status to <strong>AbbVie Inc (NYSE:ABBV)<\/strong>\u2019s hepatitis C drug to treat adult patients suffering with chronic genotype 4 hepatitis C. It is a key achievement for the company as competition among developers of hepatitis drugs intensifies. The new status reduces the regulatory review period to just six months.<\/p>\n<p style=\"text-align: justify;\"><strong>The treatment<\/strong><\/p>\n<p style=\"text-align: justify;\">AbbVie\u2019s treatment drug is the first oral, interferon-free medication under FDA assessment for patients suffering with the specific strain of the virus. There are as many as six different strains of hepatitis and Genotype 1 can be stated as the most common type of hepatitis strain found in the U.S. The other strain genotype 4 is common in Egypt, Africa and the Middle East. As per the \u201cNational Center for Biotechnology Information\u201d the epidemiology of hepatitis strain \u2018Genotype 7\u2019 has altered and has commenced to spread to several other regions in Europe through injection drug use and immigration.<\/p>\n<p style=\"text-align: justify;\"><strong>The designation<\/strong><\/p>\n<p style=\"text-align: justify;\">The U.S. FDA gives priority review status to investigational drugs that cure a serious condition and, if accepted, would offer a considerable improvement in effectiveness or safety. This status reduces the regulatory review period to six months compared to review period of at least ten months. AbbVie\u2019s treatment was also given a breakthrough therapy status in June 2014, a designation granted to investigational therapies for life threatening or serious conditions with initial clinical data that may reflect considerable improvement compared with available treatment.<\/p>\n<p style=\"text-align: justify;\"><strong>The significance<\/strong><\/p>\n<p style=\"text-align: justify;\">AbbVie Inc (NYSE:ABBV) stated that the priority status was received on basis of results from its Pearl-I study, performed in 2014, which demonstrated a 100% treatment rate for previously untreated patients or in patients in whom available treatment failed. The treatment period was 12 weeks during which patients were administered with two direct-acting antivirals. There are almost 34 million people across the globe who suffers from Genotype 4 chronic hepatitis C.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. FDA granted priority review status to AbbVie Inc (NYSE:ABBV)\u2019s hepatitis C drug to treat adult patients suffering with chronic genotype 4 hepatitis C. [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":21657,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1593,1592],"stock_ticker":[],"class_list":["post-35195","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-abbvie-inc-nyseabbv","tag-nyseabbv","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The U.S. FDA Granted Priority Review To AbbVie Inc (NYSE:ABBV) Hepatitis C Drug - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The U.S. FDA Granted Priority Review To AbbVie Inc (NYSE:ABBV) Hepatitis C Drug - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"The U.S. FDA granted priority review status to AbbVie Inc (NYSE:ABBV)\u2019s hepatitis C drug to treat adult patients suffering with chronic genotype 4 hepatitis C. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-04-27T13:33:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"456\" \/>\n\t<meta property=\"og:image:height\" content=\"190\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"The U.S. FDA Granted Priority Review To AbbVie Inc (NYSE:ABBV) Hepatitis C Drug\",\"datePublished\":\"2015-04-27T13:33:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195\"},\"wordCount\":324,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"keywords\":[\"AbbVie Inc. (NYSE:ABBV)\",\"NYSE:ABBV\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195\",\"name\":\"The U.S. FDA Granted Priority Review To AbbVie Inc (NYSE:ABBV) Hepatitis C Drug - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"datePublished\":\"2015-04-27T13:33:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"width\":456,\"height\":190},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The U.S. FDA Granted Priority Review To AbbVie Inc (NYSE:ABBV) Hepatitis C Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The U.S. FDA Granted Priority Review To AbbVie Inc (NYSE:ABBV) Hepatitis C Drug - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195","og_locale":"en_US","og_type":"article","og_title":"The U.S. FDA Granted Priority Review To AbbVie Inc (NYSE:ABBV) Hepatitis C Drug - Wall Street PR","og_description":"The U.S. FDA granted priority review status to AbbVie Inc (NYSE:ABBV)\u2019s hepatitis C drug to treat adult patients suffering with chronic genotype 4 hepatitis C. [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-04-27T13:33:21+00:00","og_image":[{"width":456,"height":190,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"The U.S. FDA Granted Priority Review To AbbVie Inc (NYSE:ABBV) Hepatitis C Drug","datePublished":"2015-04-27T13:33:21+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195"},"wordCount":324,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","keywords":["AbbVie Inc. (NYSE:ABBV)","NYSE:ABBV"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195","url":"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195","name":"The U.S. FDA Granted Priority Review To AbbVie Inc (NYSE:ABBV) Hepatitis C Drug - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","datePublished":"2015-04-27T13:33:21+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","width":456,"height":190},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-u-s-fda-granted-priority-review-to-abbvie-inc-nyseabbv-hepatitis-c-drug-35195#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"The U.S. FDA Granted Priority Review To AbbVie Inc (NYSE:ABBV) Hepatitis C Drug"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=35195"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35195\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/21657"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=35195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=35195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=35195"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=35195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}